Details der Publikation - Retraction Note: Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression

Retraction Note: Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression

Medienart:	E-Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:39
Enthalten in:	Pharmaceutical research - 39(2022), 12 vom: 11. Nov., Seite 3383-3384

Sprache:	Englisch

Beteiligte Personen:	Izadi, Sepideh [VerfasserIn] Moslehi, Asma [VerfasserIn] Kheiry, Hadiseh [VerfasserIn] Kiani, Fariba Karoon [VerfasserIn] Ahmadi, Armin [VerfasserIn] Masjedi, Ali [VerfasserIn] Ghani, Sepideh [VerfasserIn] Rafiee, Behnam [VerfasserIn] Karpisheh, Vahid [VerfasserIn] Hajizadeh, Farnaz [VerfasserIn] Atyabi, Fatemeh [VerfasserIn] Assali, Akram [VerfasserIn] tekie, Farnaz Sadat Mirzazadeh [VerfasserIn] Namdar, Afshin [VerfasserIn] Ghalamfarsa, Ghasem [VerfasserIn] Sojoodi, Mozhdeh [VerfasserIn] Jadidi-Niaragh, Farhad [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.38$jPharmakologie

Anmerkungen:	© Springer Science+Business Media, LLC, part of Springer Nature 2022

doi:	10.1007/s11095-022-03432-6

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2133159002

Internformat


LEADER	01000naa a22002652 4500
001	OLC2133159002
003	DE-627
005	20230506100059.0
007	cr uuu---uuuuu
008	230506s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11095-022-03432-6 \|2 doi
035			\|a (DE-627)OLC2133159002
035			\|a (DE-He213)s11095-022-03432-6-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a PHARM \|q DE-84 \|2 fid
084			\|a 15,3 \|2 ssgn
084			\|a 44.38$jPharmakologie \|2 bkl
100	1		\|a Izadi, Sepideh \|e verfasserin \|4 aut
245	1	0	\|a Retraction Note: Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Springer Science+Business Media, LLC, part of Springer Nature 2022
700	1		\|a Moslehi, Asma \|4 aut
700	1		\|a Kheiry, Hadiseh \|4 aut
700	1		\|a Kiani, Fariba Karoon \|4 aut
700	1		\|a Ahmadi, Armin \|4 aut
700	1		\|a Masjedi, Ali \|4 aut
700	1		\|a Ghani, Sepideh \|4 aut
700	1		\|a Rafiee, Behnam \|4 aut
700	1		\|a Karpisheh, Vahid \|4 aut
700	1		\|a Hajizadeh, Farnaz \|4 aut
700	1		\|a Atyabi, Fatemeh \|4 aut
700	1		\|a Assali, Akram \|4 aut
700	1		\|a tekie, Farnaz Sadat Mirzazadeh \|4 aut
700	1		\|a Namdar, Afshin \|4 aut
700	1		\|a Ghalamfarsa, Ghasem \|4 aut
700	1		\|a Sojoodi, Mozhdeh \|4 aut
700	1		\|a Jadidi-Niaragh, Farhad \|0 (orcid)0000-0002-4641-882X \|4 aut
773	0	8	\|i Enthalten in \|t Pharmaceutical research \|d Springer US, 1984 \|g 39(2022), 12 vom: 11. Nov., Seite 3383-3384 \|h Online-Ressource \|w (DE-627)325485291 \|w (DE-600)2036232-8 \|w (DE-576)104082380 \|x 1573-904X \|7 nnns
773	1	8	\|g volume:39 \|g year:2022 \|g number:12 \|g day:11 \|g month:11 \|g pages:3383-3384
856	4	0	\|u https://dx.doi.org/10.1007/s11095-022-03432-6 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a FID-PHARM
912			\|a SSG-OPC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.38$jPharmakologie \|q VZ \|0 106409743 \|0 (DE-625)106409743
951			\|a AR
952			\|d 39 \|j 2022 \|e 12 \|b 11 \|c 11 \|h 3383-3384

Retraction Note: Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände